Cothera Bioscience

Executive Summary

Cothera Bioscience is a private, clinical-stage biotechnology company developing novel cancer therapeutics against previously undruggable targets. Founded in 2018 and headquartered in San Diego, the company leverages a clinically validated translational platform that exploits synthetic lethality and protein degradation pathways to selectively kill cancer cells. Cothera’s lead asset, Sepantronium Bromide, is currently in a Phase 2 clinical trial (NCT05263583) for high-grade B-cell lymphoma, including double-hit lymphomas with MYC and BCL2/BCL6 rearrangements. The trial, initiated in December 2022, targets a significant unmet need in aggressive B-cell malignancies where standard therapies often fail. With a focus on hard-to-drug oncology targets, Cothera’s platform has the potential to expand into multiple indications, offering a differentiated approach in the precision oncology landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data for Sepantronium Bromide in high-grade B-cell lymphoma40% success
• TBDInitiation of Phase 1/2 trial for next-generation synthetic lethality candidate30% success
• TBDStrategic partnership or licensing deal for platform technology20% success